Related references
Note: Only part of the references are listed.Higher TIGIT+CD226- γδ T cells in Patients with Acute Myeloid Leukemia
Zhenyi Jin et al.
IMMUNOLOGICAL INVESTIGATIONS (2022)
Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia
Feng-Ting Dao et al.
SCIENTIFIC REPORTS (2021)
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
Mitsuhito Hirano et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells
Muneyoshi Futami et al.
PLOS ONE (2020)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman et al.
BLOOD (2020)
Ligand recognition by the γδ TCR and discrimination between homeostasis and stress conditions
Malte Deseke et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
Beatriz Sanchez-Correa et al.
CANCERS (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
CD8+ T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients
Mengjie Wang et al.
CLINICAL IMMUNOLOGY (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Hauke Stamm et al.
ONCOGENE (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Eric O. Long et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Adaptive resistance: A tumor strategy to evade immune attack
Sheng Yao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells
Qu Cui et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanisms of resistance to FLT3 inhibitors
S. Haihua Chu et al.
DRUG RESISTANCE UPDATES (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia
H Tamura et al.
CLINICAL CANCER RESEARCH (2005)
Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by broblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway
T Hirota et al.
ONCOGENE (2005)
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)
D Pende et al.
BLOOD (2005)
Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)
S Tahara-Hanaoka et al.
INTERNATIONAL IMMUNOLOGY (2004)
Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector
Y Bai et al.
GENE THERAPY (2003)
MLL partial tandem duplications in acute leukemia cell lines
H Quentmeier et al.
LEUKEMIA (2003)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation
M Yagita et al.
LEUKEMIA (2000)
Share Paper
